GlassScriptPhysician profile
Chadwick William Morehart
NPI 1912370792
$7,938.76
in general payments reported to CMS, 2019-2025
28 companies · $2,380 in 2025
The $2,380 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,390 · 2023: $1,917 · 2024: $2,252 · 2025: $2,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,548.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,300.29 | 2022-2025 | |
| Janssen Biotech, INC. | $824.88 | 2022-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $714.76 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.20 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Lilly USA, LLC | $328.30 | 2024-2025 | Omvoh |
| Genzyme Corporation | $316.40 | 2022-2025 | |
| Madrigal Pharmaceuticals | $292.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $290.74 | 2022-2025 | Ocaliva |
| Ardelyx, INC. | $256.32 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $217.69 | 2023-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $215.11 | 2022-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $194.67 | 2022-2025 | Linzess |
| Aimmune Therapeutics, INC. | $164.26 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $157.84 | 2022-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $130.37 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $129.27 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $115.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $104.55 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $104.46 | 2024-2025 | Vegzelma |
| Pfizer INC. | $89.40 | 2023-2025 | |
| Gilead Sciences, INC. | $75.20 | 2024-2025 | |
| Boston Scientific Corporation | $63.98 | 2022-2025 | Watchman Flx |
| Braintree Laboratories, INC. | $44.26 | 2022-2025 | Suflave |
| Fresenius Kabi USA, LLC | $44.05 | 2023 | Smoflipid |
| Ferring Pharmaceuticals INC. | $17.45 | 2023 | Rebyota |
| Novo Nordisk INC | $16.79 | 2025 | Wegovy |
| Organon LLC | $14.50 | 2023 | Hadlima |
| Micro-Tech Endoscopy USA, INC. | $9.43 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Morehart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.